The aim of this work was to establish and validate a method for detecting claudin-2 expression in routine FFPE human colon biopsies, which could be deployed for regulatory clinical bioanalysis and enable us to test the hypothesis that claudin-2 is a proof-of-mechanism biomarker for Ulcerative Colitis therapies. This evidence concerns the gene CLDN2 and ulcerative colitis.